earnings
confidence high
sentiment positive
materiality 0.75
C4 Therapeutics Q2 net loss $26M; cemsidomide MM ORR 40-50%; FDA align on Phase 2 dose by YE
C4 Therapeutics, Inc.
2025-Q2 EPS
reported -$0.74
vs consensus -$0.39
▼ miss
(-88.9%)
- Net loss of $26.0M ($0.37/share) on revenue $6.5M, down from $12.0M YoY.
- Cemsidomide Phase 1 MM data: ORR 40% at 75 µg and 50% at 100 µg; well-tolerated; highest dose 100 µg.
- Productive Type C meeting with FDA; registrational development expected to start early 2026; full data at IMS September 2025.
- Cash $223M as of June 30, 2025; runway extended to mid-2027.
- Preclinical milestone achieved under Merck KGaA collaboration; $1M earned.